Atenolol-AFT Update

We currently have a stock shortage of Atenolol-AFT (atenolol 50 mg/10 mL) oral liquid 300 mL in both Australia and New Zealand. The only product currently held by AFT Pharmaceuticals expires in October 2018.

Due to problems at the manufacturing site we do not expect new stock to be available until February 2019. We are working with the manufacturer to expedite production of new stock.

We apologise for any inconvenience that is caused by this out of stock situation but it is due to circumstances outside of our control.

November 20, 2025

AFT delivers 10th consecutive first half revenue increase

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 3…

Read More

November 12, 2025

AFT Pharmaceuticals Brings Next-Generation Liposomal Collagen and Wellness Range to the U.S. Market 

AFT Pharmaceuticals has launched its full Lipo-Sachets® range in the U.S., featuring advanced collagen and vitamin supplements powered by patented LI…

Read More

September 25, 2025

On track for $300m FY27 revenue; positive iron IV study result

– Sales tracking in line with $300 million FY27 revenue target – Clinical trial supports the potential patient benefits of novel iron IV development …

Read More